Melatonin Treatment for Induced Transient Insomnia
This study is currently recruiting participants.
Verified March 2013 by Brigham and Women's Hospital
Sponsor:
Brigham and Women's Hospital
Information provided by (Responsible Party):
Charles Andrew Czeisler, MD, PhD, Brigham and Women's Hospital
ClinicalTrials.gov Identifier:
NCT00950885
First received: July 22, 2009
Last updated: March 4, 2013
Last verified: March 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Melatonin supplements have been reported to be an effective treatment for circadian rhythm sleep disorders, including shift work dyssomnia, jet-lag, delayed sleep phase syndrome, and sleep disruption suffered by many blind individuals. However, the mechanism(s) by which melatonin affects the timing of sleep are not well-understood. The purpose of this study is to determine if melatonin improves sleep and performance on a schedule simulating eastward travel. This study will provide information regarding the mechanism of action of melatonin that will be critical for the use of melatonin as a treatment for circadian rhythm sleep disorders.
| Condition | Intervention |
|---|---|
|
Delayed Sleep Phase Disorder Jet-lag Shift-work Disorder |
Biological: Melatonin Biological: Placebo |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Basic Science |
| Official Title: | Efficacy of Melatonin Treatment in a Phase Advance Model of Transient Insomnia |
Resource links provided by NLM:
MedlinePlus related topics:
Sleep Disorders
Drug Information available for:
Melatonin
U.S. FDA Resources
Further study details as provided by Brigham and Women's Hospital:
Primary Outcome Measures:
- Circadian phase [ Time Frame: Though the last 5 days of the study ] [ Designated as safety issue: No ]
- Sleep efficiency [ Time Frame: During sleep thoughout the 7 day study ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Neurobehavioral performance [ Time Frame: During wake throughout the 7 day study ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 60 |
| Study Start Date: | September 2009 |
| Estimated Study Completion Date: | August 2014 |
| Estimated Primary Completion Date: | August 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Placebo Comparator: Placebo
placebo control group will receive 4 doses of identically-appearing capsules containing cellulose
|
Biological: Placebo
Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
|
|
Experimental: Low dose melatonin
0.5 mg melatonin
|
Biological: Melatonin
Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
|
|
Experimental: High dose
3.0 mg melatonin
|
Biological: Melatonin
Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
|
Eligibility| Ages Eligible for Study: | 18 Years to 30 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Non-smoking for at least 6 months;
- Healthy (no medical, psychiatric or sleep disorders);
- No clinically significant deviations from normal in medical history, vital signs, physical examination, blood chemistry and hematology, and ECG;
- Women of childbearing potential must agree to use an acceptable method of birth control, and must have a negative serum pregnancy test;
- Body mass index of > 18 or < 30 kg/m2;
- No drugs or medication likely to affect sleep or alertness, as determined by the investigators;
Exclusion Criteria:
- History of alcohol or substance abuse;
- Positive result on drugs of abuse screening;
- Current or past history of sleep disorders, including but not limited to obstructive sleep apnea, or any significant sleep complaint;
- Psychiatric disorder, including a history of depression or dysthymia (characterized by depressed mood on the majority of days for at least two years);
- Recent acute or chronic medical disorder, including but not limited to hepatic impairment and severe chronic obstructive pulmonary disease;
- History of intolerance or hypersensitivity to melatonin or melatonin agonists;
- Pregnancy or lactation;
- Shift work in the last 3 years;
- Transmeridian travel (2 or more time zones) in past 3 months;
- Any other scientific or medical reason, as determined by the PI, such as non-compliance with protocol or intolerance to inpatient study conditions.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00950885
Contacts
| Contact: Sean W Cain, Ph.D. | 617-732-5174 | swcain@rics.bwh.harvard.edu |
| Contact: Jeanne F Duffy, MBA, Ph.D. | 617-732-7995 | jduffy@rics.bwh.harvard.edu |
Locations
| United States, Massachusetts | |
| Brigham and Women's Hospital | Recruiting |
| Boston, Massachusetts, United States, 02115 | |
| Contact: Sean W Cain 617-732-5174 swcain@rics.bwh.harvard.edu | |
Sponsors and Collaborators
Brigham and Women's Hospital
Investigators
| Principal Investigator: | Charles A Czeisler, Ph.D., M.D. | Brigham and Women's Hospital |
More Information
No publications provided
| Responsible Party: | Charles Andrew Czeisler, MD, PhD, Baldino Professor of Sleep Medicine, Brigham and Women's Hospital |
| ClinicalTrials.gov Identifier: | NCT00950885 History of Changes |
| Other Study ID Numbers: | 1R01HL093279 |
| Study First Received: | July 22, 2009 |
| Last Updated: | March 4, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Brigham and Women's Hospital:
|
sleep alertness performance vigilance circadian |
Additional relevant MeSH terms:
|
Sleep Initiation and Maintenance Disorders Sleep Disorders, Circadian Rhythm Sleep Disorders, Intrinsic Dyssomnias Sleep Disorders Nervous System Diseases Mental Disorders Chronobiology Disorders Occupational Diseases |
Melatonin Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents |
ClinicalTrials.gov processed this record on May 22, 2013